Therapeutic Antibody Development Services
Various therapeutic antibodies devised and employed for autoimmunity have been successful, compensating the unmet medical need for immunological disorders. Our company provides cutting-edge research services to help you develop highly specific antibodies and accelerate the therapeutic antibodies development in Autoimmune Diseases & Inflammation.
Therapeutic Antibodies in Autoimmune Diseases & Inflammation
Therapeutic antibodies are biopharmaceuticals that target appropriate targets in biological bodies, which have been successfully applied to control of inflammatory responses in preclinical models and cases with Autoimmune Diseases & Inflammation. Abnormally increased cytokines, B lymphocytes that produce excessive autoantibodies, and abnormally elevated T lymphocyte activity all lead to dysfunction of the immune system. Therefore, inflammatory cytokines, mediators and receptors have been acted as biomarkers for therapeutic targets.
Fig.1 Cytokine network in systemic lupus erythematosus (Rojas M., et al., 2018)
To date, a variety of monoclonal antibodies against autoimmune diseases targeting some of the crucial cytokines have been approved around the world. Given that the pathogenesis of autoimmune diseases is not been adequately resolved, there are still vast exploratory possibilities for the development of therapeutic antibodies for more other types of Autoimmune Diseases & Inflammation.
| mAb | Target | Indication |
| Tocilizumab | IL-6R | Rheumatoid Arthritis |
| Vedolizumab | α4β7 integrin | Ulcerative Colitis, Crohn's Disease |
| Secukinumab | IL-17α | Psoriasis |
| Ixekizumab | IL-17α | Psoriasis |
| Reslizumab | IL-5 | Asthma |
| Brodalumab | IL-17R | Plaque Psoriasis |
| Sarilumab | IL-6R | Rheumatoid Arthritis |
| Sifalimumab | IFN-α | Systemic Lupus Erythematosus |
| Tildrakizumab | IL-23 p19 | Plaque Psoriasis |
| Risankizumab | IL-23 p19 | Plaque Psoriasis |
| Itolizumab | CD6 | Lupus |
| Ocrelizumab | CD20 | Multiple Sclerosis |
Therapeutic Antibody Development
Four main approaches have been used for the development of therapeutic antibodies. Mouse hybridoma technique fusing antibody-producing cells with immortalized myeloma cells is a conventional strategy to produce specific antibodies. The humanization of therapeutic antibodies is an important milestone in antibody drug development. Technologies for the generation of humanized and fully human antibodies based on phage display, transgenic mice and single B cell antibody isolation have been dramatically accelerated the process of treating Autoimmune Diseases & Inflammation.
Mouse Hybridoma, characterized by high specificity, high yield, heredity, scalability and customizability.
Phage Display, advantages lying in high throughput of spanning, high efficiency and easy purification, as well screening of mimic epitopes.
Transgenic Mouse, producing highly specific antibodies with high affinity, recognition ability against specific antigens, and customized flexibility.
Single B Cell, a promising method for efficiently and rapidly collecting naïve and antigen-stimulated antibodies in vivo with a small number of cells.
Our Services
Therapeutic antibodies for inflammatory cytokines, mediators and receptors are drugs of next generation for the therapeutics of Autoimmune Diseases & Inflammation. We provide therapeutic antibodies development for these targets, including but not limited to:
With a comprehensive capacity for the preparation of therapeutic antibodies, we provide development services and products for a wide variety of antibodies, including monoclonal antibodies, polyclonal antibodies, bispecific antibodies, etc.
Monoclonal Antibodies (mAbs)
Polyclonal Antibodies (pAbs)
Bispecific Antibodies (BiAbs)
Antibody-Drug Conjugates (ADCs)
- The Workflow of Therapeutic Antibodies Development
Target Discovery
Identification & Validation of Antigen
Antibody Generation
Hybridoma
Phage display
B cells isolation
Lead Identification
High throughput screening
In vitro bioassay
Antibody sequencing
Antibody Optimization
Antibody sequencing
Humanization
Affinity optimization
Developability improvement
Antibody Validation
In vivo function assay
In vivo safety / efficacy evaluation
Our advantages
Rigorous experimental operation and analysis
Custom project design by immunologists
High-level professional technical team
Rapid trial turnaround time
With the participation of researchers from immunology and cell engineering biology, and successful antibody development experience from a large number of practices, our company is committed to providing you with professional services for the development of therapeutic antibodies for Autoimmune Diseases & Inflammation. If you are interested in our services, please contact us for more detailed information.
Reference
- Rojas, Manuel et al. "Cytokines and Inflammatory Mediators in Systemic Lupus Erythematosus." EMJ Rheumatology 5 (2018): 83-92.